Format

Send to

Choose Destination
Cancer Prev Res (Phila). 2016 Sep;9(9):713-20. doi: 10.1158/1940-6207.CAPR-15-0384. Epub 2016 May 24.

Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Author information

1
Division of Cancer Prevention, National Cancer Institute Bethesda, Maryland. ShermanM@mail.nih.gov.
2
The Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania.
3
Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School and Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts.
4
Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
5
Facing Our Risk of Cancer Empowered (FORCE), Tampa, Florida.
6
Division of Gynecologic Oncology, University of British Columbia and BC Cancer Agency, Vancouver, BC, Canada.
7
Gynecologic Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY.
8
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
9
Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, California.
10
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Washington School of Medicine, Seattle, Washington.
11
Department of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma.
12
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
13
Division of Cancer Prevention, National Cancer Institute Bethesda, Maryland.
14
Division of Cancer Prevention, National Cancer Institute Bethesda, Maryland. Department of Gynecology and Obstetrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland.

Abstract

Women with clinically detected high-grade serous carcinomas (HGSC) generally present with advanced-stage disease, which portends a poor prognosis, despite extensive surgery and intensive chemotherapy. Historically, HGSCs were presumed to arise from the ovarian surface epithelium (OSE), but the inability to identify early-stage HGSCs and their putative precursors in the ovary dimmed prospects for advancing our knowledge of the pathogenesis of these tumors and translating these findings into effective prevention strategies. Over the last decade, increased BRCA1/2 mutation testing coupled with performance of risk-reducing surgeries has enabled studies that have provided strong evidence that many, but probably not all, HGSCs among BRCA1/2 mutation carriers appear to arise from the fallopian tubes, rather than from the ovaries. This shift in our understanding of the pathogenesis of HGSCs provides an important opportunity to achieve practice changing advances; however, the scarcity of clinically annotated tissues containing early lesions, particularly among women at average risk, poses challenges to progress. Accordingly, we review studies that have kindled our evolving understanding of the pathogenesis of HGSC and present the rationale for developing an epidemiologically annotated national specimen resource to support this research. Cancer Prev Res; 9(9); 713-20.

PMID:
27221539
PMCID:
PMC5010984
DOI:
10.1158/1940-6207.CAPR-15-0384
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center